Clinical Trial Results:
Safety and Pharmacokinetics of PATANASE® in Pediatric Patients 2 to < 6 Years of Age Who Have a History of Allergic Rhinitis
Summary
|
|
EudraCT number |
2017-003970-16 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
18 Dec 2008
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
25 Jan 2018
|
First version publication date |
25 Jan 2018
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
C-07-02
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Alcon Research Ltd
|
||
Sponsor organisation address |
6201 S. Freeway, Fort Worth, Texas, United States, 76134
|
||
Public contact |
Ophthalmology Unit, Novartis Pharmaceuticals, + 44 0127666733391, dennis.wong@novartis.com
|
||
Scientific contact |
Ophthalmology Unit, Novartis Pharmaceuticals, + 44 0127666733391, dennis.wong@novartis.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
18 Dec 2008
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
18 Dec 2008
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
18 Dec 2008
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The purpose of this study was to assess the safety and pharmacokinetic of Olopatadine Hydrochloride Nasal Spray 0.6% administered twice daily in pediatric patients 2 to < 6 years of age.
|
||
Protection of trial subjects |
Prior to the start of the study, the study protocol, the informed consent and assent documents, patient instruction sheets, the Investigator’s Brochure, as well as any advertising materials used to recruit patients were submitted to institutional review boards (IRBs) and independent ethics committees (IECs). The IRB/IECs reviewed all documents and approved required documents; copies of the approval letters were provided to Alcon. Consistent with both the IRB/IEC’s requirements and all applicable regulations, the Investigators periodically provided study updates to the IRB/IEC. A patient or parent/legal guardian (if necessary, a legally authorized representative) provided informed consent, and children signed an approved assent form when appropriate. This study was conducted in accordance with Good Clinical Practices (GCP) and the ethical principles that have their origins in the Declaration of Helsinki.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
03 Oct 2008
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United States: 132
|
||
Worldwide total number of subjects |
132
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
132
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
Subjects were recruited from 9 study centers located in the US. | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
This reporting group includes all randomized and treated subjects (132). | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Overall (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Subject, Investigator, Assessor | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Olo 0.6% 1 Spray | |||||||||||||||
Arm description |
Olopatadine Hydrochloride Nasal Spray 0.6%, 1 spray in each nostril twice daily (BID) for 14 days, 1 single dose on Day 15 | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Olopatadine Hydrochloride Nasal Spray 0.6%
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
PATANASE®
|
|||||||||||||||
Pharmaceutical forms |
Nasal spray
|
|||||||||||||||
Routes of administration |
Nasal use
|
|||||||||||||||
Dosage and administration details |
1 spray in each nostril BID for 14 days, 1 single dose on the 15th day
|
|||||||||||||||
Arm title
|
Veh 1 Spray | |||||||||||||||
Arm description |
Olopatadine Hydrochloride Nasal Spray Vehicle, 1 spray in each nostril BID for 15 days | |||||||||||||||
Arm type |
Placebo | |||||||||||||||
Investigational medicinal product name |
Olopatadine Hydrochloride Nasal Spray Vehicle
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Nasal spray
|
|||||||||||||||
Routes of administration |
Nasal use
|
|||||||||||||||
Dosage and administration details |
1 spray in each nostril BID for 15 days
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Olo 0.6% 1 Spray
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Olopatadine Hydrochloride Nasal Spray 0.6%, 1 spray in each nostril twice daily (BID) for 14 days, 1 single dose on Day 15 | ||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Veh 1 Spray
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Olopatadine Hydrochloride Nasal Spray Vehicle, 1 spray in each nostril BID for 15 days | ||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Olo 0.6% 1 Spray
|
||
Reporting group description |
Olopatadine Hydrochloride Nasal Spray 0.6%, 1 spray in each nostril twice daily (BID) for 14 days, 1 single dose on Day 15 | ||
Reporting group title |
Veh 1 Spray
|
||
Reporting group description |
Olopatadine Hydrochloride Nasal Spray Vehicle, 1 spray in each nostril BID for 15 days |
|
||||||||||
End point title |
Number of Serious Adverse Events (SAEs) [1] | |||||||||
End point description |
Adverse events were defined as any change (expected or unexpected) in a subject’s nasal and/or medical health that occurred after initiation of study treatment.
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
Up through Day 15
|
|||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No formal statistical analysis was planned or conducted for this primary endpoint. Descriptive tables for adverse events were provided. |
||||||||||
|
||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Maximum plasma concentration (Cmax) [2] | ||||||||||||||
End point description |
Plasma concentrations of olopatadine and its active metabolites [N-desmethyl olopatadine (M1), N-didesmethyl olopatadine (M2), and olopatadine N-oxide (M3)] were measured, and pharmacokinetic (PK) parameters for olopatadine and M1, M2, and M3 were estimated using a population PK model. There were no measurable plasma concentrations for M2. Mean systemic exposure parameters were based on post hoc individual parameter estimates.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Up through Day 15
|
||||||||||||||
Notes [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Only subjects administered experimental drug were analyzed. Descriptive tables for pharmacokinetic parameters were provided. |
|||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Time to attain Cmax from time of last dose (Tmax) [3] | ||||||||||||||
End point description |
Plasma concentrations of olopatadine and its active metabolites, M1, M2, and M3 were measured, and PK parameters were estimated using a population PK model. There were no measurable plasma concentrations for M2. Mean systemic exposure parameters were based on post hoc individual parameter estimates.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Up to Day 15
|
||||||||||||||
Notes [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Only subjects administered experimental drug were analyzed. Descriptive tables for pharmacokinetic parameters were provided. |
|||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Area under the plasma concentration - time curve (AUC0-12) [4] | ||||||||||||||
End point description |
Plasma concentrations of olopatadine and its active metabolites, M1, M2, and M3 were measured, and PK parameters were estimated using a population PK model. There were no measurable plasma concentrations for M2. Mean systemic exposure parameters were based on post hoc individual parameter estimates. AUC0-12 at steady state was determined as the ratio of dose to clearance of the analyte.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Up to Day 15
|
||||||||||||||
Notes [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Only subjects administered experimental drug were analyzed. Descriptive tables for pharmacokinetic parameters were provided. |
|||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Only total subjects affected by non-serious AEs that occur at >5% are reported.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
11.0
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Olo 0.6% 1 Spray
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Olopatadine Hydrochloride Nasal Spray 0.6%, 1 spray in each nostril twice daily (BID) for 14 days, 1 single dose on the 15th day | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Veh 1 Spray
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Olopatadine Hydrochloride Nasal Spray Vehicle, 1 spray in each nostril BID for 15 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |